VNDA Vanda Pharmaceuticals Inc.
$5.09▲ +0.99%
Healthcare
Other
After hours
$5.16▲ +1.38%
Sep 11, 7:30 PM ET
Volume 698.1K
Avg Volume (10D) 669.2K
Key Metrics & Fundamentals
Market Cap
$307.76M
P/E Ratio
–
Div Yield
–%
52W Range
4.27 - 9.94
% vs 50 MA
-6.36%
% vs 200 MA
-22.63%
RSI-14
42.0
MACD Histogram
-0.0200
Beta (1Y vs SPY)
0.79
Free Cash Flow
-$31.26M
Gross Rev
$50.53M
Gross Profit
$46.97M
EBITDA
-$60.10M
COGS
$3.56M
Operating Exp
$110.78M
Operating Income
-$63.81M
EBIT
-$63.81M
Pretax Income
-$62.38M
Net Income
-$62.51M
EPS (Diluted)
-1.04
Price & Volume History
Loading chart…
Recent News
Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences
PR Newswire · Sep 2, 2026 8:30 PM
BetterLife Pharma Appoints Charles Duncan as Director and Chair of the Audit Committee
TMX Newsfile · Aug 31, 2026 12:00 PM
Vanda Pharmaceuticals' Skin Disease Drug Gets EU Orphan Drug Designation
MT Newswires · Aug 24, 2026 11:41 AM
Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission
PR Newswire · Aug 24, 2026 11:00 AM
NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.
PR Newswire · Aug 22, 2026 7:16 PM
Vanda (VNDA) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 12, 2026 11:13 PM
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
Zacks · Aug 11, 2026 1:44 PM
Vanda Pharmaceuticals Q2 Earnings Call Highlights
MarketBeat · Aug 6, 2026 7:03 AM
Vanda Pharmaceuticals Inc. Q2 2026 Earnings Call Summary
Moby · Aug 6, 2026 3:30 AM
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates
Zacks · Aug 5, 2026 9:10 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See VNDA's money flow as a full page
Social Sentiment
Avg -0.30 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.